Medicine

National Kidney Foundation Publishes 23 Recommendations to Move Thousands of Patients from Dialysis to Transplant

Medical specialties, Medicine, Clinical medicine, National Kidney Foundation, Kidney diseases, Kidney transplantation, Kidney disease, Organ transplantation, Kidney failure, National Kidney Foundation Singapore
Tuesday, July 27, 2021 - 1:04pm

Today, while nearly 100,000 people are on the waitlist for a kidney transplant , only 22,817 Americans received a kidney transplant in 2020.

Key Points: 
  • Today, while nearly 100,000 people are on the waitlist for a kidney transplant , only 22,817 Americans received a kidney transplant in 2020.
  • Research recommendations developed by the panel center on seven key priorities:
    Improve management and readiness of the kidney waitlist.
  • Hispanic or Latino people are 1.3 times more likely than non-Hispanic or non-Latino people to have kidney failure.
  • The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit www.kidney.org .

BioHarvest Sciences Inc. Appoints Two Top Ranked Law Firms in the US and Canada to Pursue Regulatory Approvals of Its Upcoming Cannabis and Hemp Products

Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Cannabis, Cannabis smoking, Euphoriants, Medical cannabis, Hemp
Tuesday, July 27, 2021 - 1:00pm

Dr. Applebaum, who joined BioHarvest in November 2020 as a senior consultant, is now expanding her role to head all the Cannabis regulatory affairs in North America.

Key Points: 
  • Dr. Applebaum, who joined BioHarvest in November 2020 as a senior consultant, is now expanding her role to head all the Cannabis regulatory affairs in North America.
  • Lewis Retik, a partner at GOWLING WLG, said: "In recent years, BioHarvest has emerged as a major disruptor in the global nutraceutical and Cannabis sectors.
  • With our technology, we believe we can help meet the demand for high quality, consistent and sustainable medicinal and wellbeing products.
  • As BioHarvest gets closer to full scale-up, and subsequently the commercialization of its Cannabis and hemp products, regulatory compliance is key."

electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones

Headaches, Medicine, Branches of biology, Symptoms and signs, Pain management, Neurological disorders, Migraine, Cluster headache, Headache, ElectroCore, Electrotherapy, Migraine treatment
Tuesday, July 27, 2021 - 1:00pm

11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.

Key Points: 
  • 11,065,444 to electroCore, relating to the use of a mobile phone for stimulating the trigeminal nerve to treat disorders.
  • One or more electrodes apply electrical impulses through the patient's skin modulating a targeted nerve to treat the medical condition.
  • This newly allowed patent is owned by electroCore and is the latest U.S. patent to issue in connection with the companys non-invasive development program for pain.
  • The company's current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

Medicine, Clinical medicine, Medical specialties, Anorectics, Breakthrough therapy, Peptides, Setmelanotide, Obesity, Rare disease, Disease
Tuesday, July 27, 2021 - 1:00pm

ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.
  • A webcast of the call will also be available under Events & Presentations in the Investor Relations section of the Rhythm website at ir.rhythmtx.com.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.

Antibe Therapeutics Provides July 2021 Corporate Update

Biotechnology, Pharmaceutical, Health, Clinical trials, Antibe Therapeutics, Forward-looking statement, Medicine, Screening, Articles, Health sciences
Tuesday, July 27, 2021 - 12:00pm

Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.

Key Points: 
  • Antibe is taking a comprehensive approach to maximizing the likelihood of a successful Phase III program outcome.
  • The program also combines several state-of-the-art aspects, including the hiring of leading providers of bioanalytic, quality control and data management services.
  • The latter will enable us to track and manage screening and enrollment in real-time, ensuring that the subject population matches trial criteria.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

iXensor Levels Up PixoTest Covid-19 Ag Test With The Launch Of PixoHealth Data Management Platform As The Security Solution For The New Normalcy

Medicine, Branches of biology, Medical terminology, Medical tests, Health sciences, Point-of-care testing, COVID-19, Glucose meter, Web portal, Severe acute respiratory syndrome coronavirus
Tuesday, July 27, 2021 - 12:32pm

In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest POCT Analyzer simultaneously.

Key Points: 
  • In addition, the PixoHealth Pass Admin Web Portal synchronizes multi-source COVID-19 related health data and rapid test results from PixoHealth Pass App users and PixoTest POCT Analyzer simultaneously.
  • The utilization of PixoHealth Pass Admin Web Portal, PixoTest POCT Analyzer and PixoHealth Pass App fully digitizes the data management processes with a one-time setup.
  • In addition, PixoHealth Pass Admin App allows organizations to configure health-data based access management rules for keeping SARS-CoV-2 from causing cluster infections.
  • In 2017, iXensor introduced the PixoTest Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test.

LifeSignals receives FDA 510 (k) Approval for LifeSignals LX1550 Multiparameter Remote Monitoring Platform

Medical specialties, Medicine, Health care, Food and Drug Administration, United States Public Health Service, Monitoring
Tuesday, July 27, 2021 - 12:00pm

FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.

Key Points: 
  • FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.
  • Clinicians and Care Providers can access the cloud-based remote monitoring dashboard to view patient physiological data and manage alert settings.
  • The Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location.
  • "This FDA 510 (k) approval marks another major milestone in the company's development and mission.

LifeSignals receives FDA 510 (k) Approval for LifeSignals LX1550 Multiparameter Remote Monitoring Platform

Medical specialties, Medicine, Clinical medicine, Anesthesia, Intensive care medicine, Monitoring, Nanomedicine, Vital signs
Tuesday, July 27, 2021 - 12:00pm

FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform. This follows recent CE marking and is further validation of LifeSignals' drive to create innovative wireless platforms which can be used by clinicians for the continuous collection of patient physiological data at home and in healthcare settings.

Key Points: 
  • FREMONT, Calif., July 27, 2021 /PRNewswire/ -- LifeSignals Inc., today announced it has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform.
  • Clinicians and Care Providers can access the cloud-based remote monitoring dashboard to view patient physiological data and manage alert settings.
  • The Remote Monitoring Platform is designed to enable healthtech companies to rapidly enhance their product and service portfolios to provide vital sign monitoring to the widest possible patient base, from any location.
  • Our focus now is to rapidly introduce low-cost remote vital sign monitoring to US healthtech companies looking to expand their services and improve patient care."

Encyclopedia of Respiratory Medicine. 2021 Edition - ResearchAndMarkets.com

Health, Pharmaceutical, Pulmonology, Respiratory disease, Medicine, Lung, Respiratory diseases, Respiratory therapist
Tuesday, July 27, 2021 - 11:35am

The "Encyclopedia of Respiratory Medicine.

Key Points: 
  • The "Encyclopedia of Respiratory Medicine.
  • Encyclopedia of Respiratory Medicine explores the key processes of lung diseases and their diagnosis and management.
  • Written in at a time when the globe is in the grip of respiratory pandemic, lung disease has never been so prominent in the public and political conscious.
  • This new edition will provide new researchers in respiratory medicine with a solid foundation in unfamiliar topics and will update more experienced researchers seeking to step outside their core areas of research to put their work into a broader context.

Global Medical Marijuana Market to 2027 - ResearchAndMarkets.com

Health, Pharmaceutical, Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Cannabis, Entheogens, Euphoriants, Medical cannabis
Tuesday, July 27, 2021 - 11:15am

The "Global Medical Marijuana Market to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Medical Marijuana Market to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Increase in awareness regarding various medical applications such as appetite enhancement, pain management, and reducing eye pressure is the key driving factor which is expected to boost the global medical marijuana market growth.
  • However, Medical marijuana is not approved by USFDA (Food and Drug Administration) for the treatment of cancer which is major restraining factor which is expected to hamper the global medical marijuana market growth.
  • Global Medical Marijuana Market is segmented into route of administration such as Oral, Inhalation, and Topical.